Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Mezzion Pharma Statistics

Total Valuation

Mezzion Pharma has a market cap or net worth of KRW 1.74 trillion. The enterprise value is 1.71 trillion.

Market Cap	1.74T
Enterprise Value	1.71T

Important Dates

The next estimated earnings date is Tuesday, November 11, 2025.

Earnings Date	Nov 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Mezzion Pharma has 30.11 million shares outstanding. The number of shares has increased by 0.98% in one year.

Current Share Class	30.11M
Shares Outstanding	30.11M
Shares Change (YoY)	+0.98%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	9.45%
Owned by Institutions (%)	4.84%
Float	21.72M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	220.44
PB Ratio	42.19
P/TBV Ratio	43.92
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-74.06
EV / Sales	216.94
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-158.12

Financial Position

The company has a current ratio of 1.11, with a Debt / Equity ratio of 0.24.

Current Ratio	1.11
Quick Ratio	0.82
Debt / Equity	0.24
Debt / EBITDA	n/a
Debt / FCF	-0.92
Interest Coverage	-36.26

Financial Efficiency

Return on equity (ROE) is -47.98% and return on invested capital (ROIC) is -14.84%.

Return on Equity (ROE)	-47.98%
Return on Assets (ROA)	-9.53%
Return on Invested Capital (ROIC)	-14.84%
Return on Capital Employed (ROCE)	-30.17%
Revenue Per Employee	437.92M
Profits Per Employee	-1.28B
Employee Count	18
Asset Turnover	0.09
Inventory Turnover	1.15

Taxes

In the past 12 months, Mezzion Pharma has paid 2.72 billion in taxes.

Income Tax	2.72B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +90.54% in the last 52 weeks. The beta is 0.42, so Mezzion Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.42
52-Week Price Change	+90.54%
50-Day Moving Average	41,710.00
200-Day Moving Average	35,752.50
Relative Strength Index (RSI)	75.36
Average Volume (20 Days)	190,687

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mezzion Pharma had revenue of KRW 7.88 billion and -23.09 billion in losses. Loss per share was -770.43.

Revenue	7.88B
Gross Profit	1.61B
Operating Income	-12.70B
Pretax Income	-20.37B
Net Income	-23.09B
EBITDA	-11.72B
EBIT	-12.70B
Loss Per Share	-770.43

Balance Sheet

The company has 37.55 billion in cash and 10.00 billion in debt, giving a net cash position of 27.55 billion or 914.77 per share.

Cash & Cash Equivalents	37.55B
Total Debt	10.00B
Net Cash	27.55B
Net Cash Per Share	914.77
Equity (Book Value)	41.18B
Book Value Per Share	1,367.63
Working Capital	5.00B

Cash Flow

In the last 12 months, operating cash flow was -10.67 billion and capital expenditures -142.31 million, giving a free cash flow of -10.81 billion.

Operating Cash Flow	-10.67B
Capital Expenditures	-142.31M
Free Cash Flow	-10.81B
FCF Per Share	-359.12

Margins

Gross margin is 20.43%, with operating and profit margins of -161.12% and -292.93%.

Gross Margin	20.43%
Operating Margin	-161.12%
Pretax Margin	-258.40%
Profit Margin	-292.93%
EBITDA Margin	-148.64%
EBIT Margin	-161.12%
FCF Margin	n/a

Dividends & Yields

Mezzion Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.98%
Shareholder Yield	n/a
Earnings Yield	-1.33%
FCF Yield	-0.62%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 5, 2022. It was a forward split with a ratio of 3.

Last Split Date	Apr 5, 2022
Split Type	Forward
Split Ratio	3

Scores

Mezzion Pharma has an Altman Z-Score of 9.77 and a Piotroski F-Score of 2.

Altman Z-Score	9.77
Piotroski F-Score	2